The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) in its updated formulation targets current SARS-CoV-2 variants and remains a key product in Pfizer’s vaccine portfolio. This product is driving the price of Pfizer Inc. stock (ISIN US7170811035).

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) sits in a chilled tray, clear liquid catching the fluorescent light as a nurse shakes the vial gently before drawing up a dose. For Albert Bourla, the longtime Pfizer chief executive, this small bottle remains a strategic product well beyond the initial pandemic emergency.

Updated mRNA formula for current variants

Comirnaty is an mRNA-based COVID-19 vaccine jointly developed by Pfizer and the German biotech company BioNTech, marketed globally under the Comirnaty brand name. The vaccine uses a nucleoside-modified messenger RNA that encodes the SARS-CoV-2 spike protein, delivered in lipid nanoparticles. The mRNA instructs human cells to produce the spike protein transiently, which then triggers an immune response that helps the body recognize and respond quickly to future exposure.

The original Comirnaty formulation targeted the ancestral strain of SARS-CoV-2, but regulators have since approved updated monovalent formulations that match evolving variants. An updated Comirnaty version adapted to the Omicron XBB.1.5 lineage received approvals and authorizations from regulators such as the U.S. Food and Drug Administration, the European Medicines Agency and others for use in various age groups. BioNTech and Pfizer have continued to submit data packages on variant-adapted formulations as part of their ongoing collaboration agreements on mRNA vaccines and therapeutics.

Dosing, age groups and formulations

The Pfizer-BioNTech COVID-19 Vaccine is available in multiple formulations and strengths, tailored to different age groups. For adults and adolescents, updated monovalent formulations are supplied in vials that must be stored at ultra-low temperatures and thawed before use, with each multidose vial containing several doses. For children, Pfizer and BioNTech offer lower-dose pediatric formulations, typically distinguished by different cap colors and specific dosing schedules defined by regulators and health authorities.

In the United States, the FDA details Comirnaty and the Pfizer-BioNTech COVID-19 Vaccine in its labeling and fact sheets, covering indications, dosing and safety information. In the European Union, the EMA provides a public assessment report and product information documents, including dosage recommendations and storage conditions. On its corporate site, Pfizer lists Comirnaty as an mRNA vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2, clarifying age ranges subject to each regulatory jurisdiction.

Manufacturing, distribution and cold chain

Manufacturing Comirnaty requires a tightly controlled global supply chain, combining mRNA production, lipid nanoparticle formulation and vial filling at multiple sites in the United States and Europe. BioNTech originally led mRNA production at facilities in Germany, while Pfizer contributed large-scale manufacturing capacity and its established vaccine network. Both companies have reported investments in expanding capacity and adapting facilities to support ongoing demand for updated formulations.

The cold chain around Comirnaty remains demanding compared with many traditional vaccines. Ultra-low temperature freezers and temperature-validated transport boxes keep the product within a narrow range until it reaches vaccination centers. Once thawed, the liquid vials are often stored in standard refrigerators for a limited time, and staff must follow clear protocols for handling, mixing if required and discarding partially used vials at the end of their in-use window. This has led to continued attention from health systems to logistics, wastage rates and appointment scheduling.

Safety profile and regulatory oversight

Regulators such as the FDA and EMA emphasize that Comirnaty and the related Pfizer-BioNTech COVID-19 Vaccine underwent large randomized controlled trials before initial authorization, followed by extensive real-world safety monitoring. Common side effects include pain at the injection site, fatigue, headache, muscle pain and chills, typically resolving within a few days. Rare side effects, such as myocarditis and pericarditis primarily in younger males, are highlighted in product information and fact sheets, with guidance on diagnosis and management. Safety data are regularly updated as new batches of real-world evidence accumulate from national pharmacovigilance systems.

The EMA’s public assessment report for Comirnaty sets out in detail the benefit-risk balance across age groups and across different phases of the pandemic, concluding that the vaccine’s benefits in preventing COVID-19 outweigh its risks under authorized conditions of use. The FDA similarly maintains updated labeling and safety communications, including information about variant-adapted formulations. Pfizer and BioNTech have publicly indicated that they continue to monitor safety and efficacy data, and to share information with authorities as part of their obligations under conditional approvals or full licenses.

Role in Pfizer portfolio and stock context

For Pfizer, the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) has shifted from an emergency pandemic product to a recurring, though more volatile, revenue line that depends on national vaccination strategies and variant epidemiology. Investors now watch not only uptake in seasonal booster campaigns but also how efficiently Pfizer manages manufacturing costs, inventories and potential combination vaccines that might pair COVID-19 with influenza or RSV in a single shot. On the stock market, Pfizer Inc. stock trades on the New York Stock Exchange under the ticker PFE, and analysts routinely examine Comirnaty’s sales trajectory as part of their broader view of Pfizer’s vaccine and antiviral portfolio.

Key facts about Comirnaty

• Product: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
• Manufacturer: Pfizer Inc. / BioNTech SE
• Category: B2B/Pro line (vaccine, healthcare)
• Market launch: Initial emergency use authorizations in late 2020, followed by full approvals and updated variant-adapted formulations in subsequent years
• MSRP / Price: Pricing negotiated primarily via government and institutional contracts; publicly disclosed list prices and tender terms vary by market
• Availability: Available in multiple countries subject to local regulatory authorizations, with adult and pediatric formulations
• Target group: Individuals from specific age groups eligible for COVID-19 vaccination or booster doses as defined by national health authorities
• Highlight / USP: mRNA platform with variant-updated formulations and large real-world safety and effectiveness dataset